Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combined with radiotherapy for unresectable advanced or recurrent primary liver cancer
ChiCTR2400092778Phase 4Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in liver cancer and hepatocellular carcinoma (HCC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Adverse events. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
liver cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400092778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092778.